Goldman Sachs
ARLZ

Goldman Sachs’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Goldman Sachs’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-68,301
Closed -$24K – 6027
2018
Q2 		$24K Sell
68,301
-3,261
-5% -$2.67K ﹤0.01% 5479
2018
Q1 		$107K Sell
71,562
-190,044
-73% -$332K ﹤0.01% 5263
2017
Q4 		$371K Buy
261,606
+160,621
+159% +$264K ﹤0.01% 5042
2017
Q3 		$231K Buy
100,985
+3,805
+4% +$5.09K ﹤0.01% 5668
2017
Q2 		$131K Sell
97,180
-24,314
-20% -$35.1K ﹤0.01% 6012
2017
Q1 		$260K Buy
121,494
+354
+0.3% +$1.33K ﹤0.01% 5553
2016
Q4 		$534K Sell
121,140
-92,643
-43% -$440K ﹤0.01% 5005
2016
Q3 		$1.04M Buy
213,783
+92,111
+76% +$420K ﹤0.01% 4367
2016
Q2 		$402K Buy
121,672
+90,831
+295% +$343K ﹤0.01% 5064
2016
Q1 		$109K Buy
+30,841
New +$159K ﹤0.01% 6039

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Goldman Sachs's ARLZ Position: Q3 2018 in Review

Goldman Sachs sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 68,301 shares — an estimated $24K sold.

Goldman Sachs first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $1.04M in Q3 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Goldman Sachs reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Goldman Sachs sold 68,301 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $24K.
  • Goldman Sachs first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
  • Goldman Sachs's Aralez Pharmaceuticals Inc. position peaked at $1.04M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Goldman Sachs's 13F filing for Q3 2018, filed 14 Nov 2018.